"The US Food and Drug Administration (FDA) has approved a foam containing calcipotriene and betamethasone dipropionate (Enstilar, Leo Pharma Inc) for topical treatment of plaque psoriasis in adults 18 years of age and older, according to a "...
Sorilux Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Sorilux (calcipotriene) Foam, 0.005% is a manmade form of vitamin D3 used for the topical treatment of plaque psoriasis in patients aged 18 years and older. Common side effects of Sorilux Foam include:
- skin redness
- rash, and
- itching in the treated area
Apply a thin layer dose of Sorilux Foam twice daily to the affected areas and rub in gently and completely. Sorilux may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Sorilux should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Sorilux (calcipotriene) Foam, 0.005% Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Sorilux FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
SORILUX (calcipotriene foam) Foam was studied in three-vehicle controlled trials. Seven hundred and thirty one subjects with plaque psoriasis, including 473 exposed to SORILUX (calcipotriene foam) Foam were treated twice daily for 8 weeks.
Adverse events reported in greater than 1% of subjects and in a higher rate in subjects treated with SORILUX (calcipotriene foam) Foam compared to vehicle were limited to erythema.
Read the entire FDA prescribing information for Sorilux (Calcipotriene Foam)
Additional Sorilux Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.